One area of interest is whether ketogenic diets, which are high in fat and low in carbohydrates, might be helpful to people with treatment-resistant depression.

The 2024 increase is the same as last year's increase for family coverage. The foundation’s annual survey of employer health benefits also found that only 18% of large employers (200 employees are more) are covering the GLP-1 weight loss drugs.

If approved, elinzanetant would be another non-hormonal option for menopausal women seeking hot flash relief.

Apitegromab works by targeting a protein called myostatin that limits muscle growth and is designed to be used alongside existing spinal muscular atrophy (SMA) treatments.

The results showed that 26% of patients who received tulisokibart achieved clinical remission at week 12 compared with 1% of those who received placebo.

More research on clinical meaningfulness is on the way, according to Stephanie Graff, M.D., FACP, FASCO.

Early trial data of two virally suppressed, breast-feeding women with HIV shows that there may be less of a risk of HIV transmission during breastfeeding than previously believed.

Jill Zouzoulas, M.D., of Tryon Medical Partners in Charlotte, North Carolina, and Jennifer Seminerio, M.D., of University of Southern Florida Health in Tampa, Florida, discussed the biologics and the pros and cons of the intravenous and subcutaneous delivery methods in Managed Healthcare Executive’s K-Cast video series.

Here’s what you missed this week on Managed Healthcare Executive.